New tracker goes beyond dose logging to model estimated plasma levels over time, including downstream hormone cascades for GH-secretagogue stacks
KINGMAN, Ariz., Sept. 8, 2026 /PRNewswire/ -- Baya Lobo LLC today announced the web launch of Amino Minder (aminominder.com), a peptide, GLP-1, TRT, and HRT protocol tracker built around a feature no competing app currently claims: a real pharmacokinetic (PK) engine that estimates and graphs a user's plasma level for each tracked compound over time, rather than simply logging that a dose was taken.
Most peptide-tracking apps on the market function as digital logbooks — a calendar of doses, reminders, and inventory. Amino Minder's PK engine goes further, using standard one-compartment absorption/elimination modeling to show users a rise-and-decay curve for every compound they log, adjustable for route of administration, individual half-life, and a user-configurable clearance modifier. For compounds like the GHRH- and GHRP-class growth-hormone secretagogues — where the injected peptide triggers a downstream cascade of natural GH release, which in turn drives a separate, slower IGF-1 response — Amino Minder models that full chain, including synergy effects when GHRH- and GHRP-class compounds are stacked together, a combination known to produce a greater GH response than either compound alone.
Read More: https://jornalwebdigital.blogspot.com/p/prnewswirenews.html?rkey=20260908PH42520&filter=28399
0 Comments